GM-CSF, human recombinant
Cat# P1012-100ug
Size : 100ug
Brand : APExBIO Technology
Contact local distributor :
Phone : +1 850 650 7790
- Home
- Peptides & Proteins
- Recombinant Proteins
- Cytokines
- GM-CSF, human recombinant
GM-CSF, human recombinant
mRNA synthesis
In vitro transcription of capped mRNA with modified nucleotides and Poly(A) tail
Tyramide Signal Amplification (TSA)
TSA (Tyramide Signal Amplification), used for signal amplification of ISH, IHC and IC etc.
Phos Binding Reagent Acrylamide
Separation of phosphorylated and non-phosphorylated proteins without phospho-specific antibody
Cell Counting Kit-8 (CCK-8)
A convenient and sensitive way for cell proliferation assay and cytotoxicity assay
Inhibitor Cocktails
Protect the integrity of proteins from multiple proteases and phosphatases for different applications.
Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) is secreted by a number of different cell types (including activated T cells, B cells, macrophages, mast cells, endothelial cells and fibroblasts) in response to cytokine or immune and inflammatory stimulation. It was initially characterized as a growth factor that can support the in vitro colony formation of granulocyte-macrophage progenitors and has functions of stimulates the growth and differentiation of hematopoietic precursor cells from various lineages. GM-CSF has also been reported to have a functional role on non-hematopoietic cells and can induce human endothelial cells to migrate and proliferate. Additionally, it can stimulate the proliferation of a number of tumor cell lines, including osteogenic sarcoma, carcinoma and adenocarcinoma cell lines. Human GM-CSF shares 54 % sequences identity with mouse GM-CSF, but has no biological effects across species. GM-CSF is used as a medication to stimulate the production of white blood cells following chemotherapy and has also recently been evaluated in clinical trials for its potential as a vaccine adjuvant in HIV-infected patients.
Reference:
1. Wang JM, Chen ZG, Colotta F, et al. 1988. Behring Inst Mitt: 270-3
2. 1989. N Engl J Med, 320: 253-4
3. Nissen-Druey C. 1989. Nouv Rev Fr Hematol, 31: 99-101
4. Eager RandNemunaitis J. 2005. Mol Ther, 12: 18-27
5. Tran T, Fernandes DJ, Schuliga M, et al. 2005. Br J Pharmacol, 145: 123-31.
| Gene ID | 1437 |
| Accession # | P04141 |
| Alternate Names | Granulocyte/Macrophage Colony-Stimulating Factor, CSF-2, MGI-1GM, Pluripoietin-α |
| Source | Escherichia coli. |
| M.Wt | Approximately 14.5 kDa, a single non-glycosylated polypeptide chain containing 127 amino acids. |
| AA Sequence | APARSPSPST QPWEHVNAIQ EARRLLNLSR DTAAEMNETV EVISEMFDLQ EPTCLQTRLE LYKQGLRGSL TKLKGPLTMM ASHYKQHCPP TPETSCATQI ITFESFKENL KDFLLVIPFD CWEPVQE |
| Appearance | Sterile Filtered White lyophilized (freeze-dried) powder. |
| Stability & Storage | Use a manual defrost freezer and avoid repeated freeze-thaw cycles. - 12 months from date of receipt, -20 to -70 °C as supplied. - 1 month, 2 to 8 °C under sterile conditions after reconstitution. - 3 months, -20 to -70 °C under sterile conditions after reconstitution. |
| Formulation |
Lyophilized from a 0.2 μm filtered concentrated solution in PBS, pH 7.4. |
| Reconstitution | We recommend that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute in sterile distilled water or aqueous buffer containing 0.1 % BSA to a concentration of 0.1-1.0 mg/mL. Stock solutions should be apportioned into working aliquots and stored at ≤ -20 °C. Further dilutions should be made in appropriate buffered solutions. |
| Biological Activity | Fully biologically active when compared to standard. The ED50 as determined by a cell proliferation assay using human TF-1 cells is less than 0.1 ng/ml, corresponding to a specific activity of > 1.0 × 107 IU/mg. |
| Shipping Condition | Gel pack. |
| Handling | Centrifuge the vial prior to opening. |
| Usage | For Research Use Only! Not to be used in humans. |
| Determined by the dose-dependent stimulation of the proliferation of human TF-1 cells. | ||||||
| ED50 | < 0.1 ng/ml. | |||||
| Specific activity | > 1*107 units/mg. | |||||
- Purity > 98 % by SDS-PAGE and HPLC analyses.
-
Datasheet
Endotoxin Level: Less than 1.0 EU/μg of rHuGM-CSF as determined by LAL method.